Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline

European Respiratory Journal

Volumn 19, Issue 5, 2002, Pages 865-871

  Richter, K ^a   Janicki, S ^a   Jorres R A ^a   Magnussen, H ^a  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

Author keywords

Exercise induced asthma; Formoterol; Protection; Salmeterol; Terbutaline

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; PLACEBO; SALMETEROL; TERBUTALINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; DRUG DERIVATIVE; ETHANOLAMINE DERIVATIVE; SALBUTAMOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BRONCHODILATATION; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG POTENCY; EXERCISE INDUCED ASTHMA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALER; MALE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPIROMETER; SPIROMETRY; DRUG EFFECT; INHALATIONAL DRUG ADMINISTRATION; LUNG VENTILATION; MIDDLE AGED; TIME;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ASTHMA, EXERCISE-INDUCED; BRONCHODILATOR AGENTS; COMPARATIVE STUDY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; HUMAN; MALE; MIDDLE AGE; PULMONARY VENTILATION; SPIROMETRY; SUPPORT, NON-U.S. GOV'T; TERBUTALINE; TIME FACTORS; HUMANS; MIDDLE AGED;

EID: 0036014529     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.02.00228502     Document Type: Article

References (24)

1. British guidelines on asthma management. 1995 Review and position statement
2. National Asthma Education and Prevention Program: Guidelines for the diagnosis and management of asthma
3. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma
4. Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm
5. Protective effect and duration of action of formoterol aerosol on exercise-induced asthma
6. Prophylaxis of exercise-induced asthma with inhaled formoterol, a long-acting beta 2-adrenergic agonist
7. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: Onset of action, duration of effect and potency
8. Modulation of inherent tone of human airways in vitro
9. Methylxanthines inhibit exercise-induced bronchoconstriction at low serum theophylline concentration and in a dose-dependent fashion
10. Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizer
11. Duration of protection by inhaled salmeterol in exercise-induced asthma
12. Salmeterol in exercise-induced bronchoconstriction in asthmatic children: Comparison of two doses
13. American Thoracic Society
14. An evaluation of pharmacotherapy for exercise-induced asthma
15. Inhibition of the bronchial response to respiratory heat exchange by increasing doses of terbutaline sulphate
16. Salmeterol versus formoterol in patients with moderately severe asthma: Onset and duration of action
17. Trial of a terbutaline aerosol in the treatment of asthma and a comparison of its effects with those of a salbutamol aerosol
18. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction
19. Assessment of bronchoalveolar cell and mediator response to isocapnic hyperpnea in asthma
20. 4 after exercise challenge in children with asthma
21. Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204,219, a potent leukotriene D4 antagonist
22. Formoterol on airway smooth muscle and human lung mast cells: A comparison with salbutamol and salmeterol
23. Dispersed human lung mast cells. Pharmacologic aspects and comparison with human lung tissue fragments
24. Salmeterol: A potent and long-acting inhibitor of inflammatory mediator release from human lung